Lanean...
Characterizing expanded access and compassionate use programs for experimental drugs
OBJECTIVE: We sought to determine the characteristics of “expanded access” and “compassionate use” programs registered in ClinicalTrials.gov and to determine the percentage of drugs provided through these programs that ultimately received FDA marketing approval. RESULTS: We identified 398 expanded a...
Gorde:
| Argitaratua izan da: | BMC Res Notes |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5534121/ https://ncbi.nlm.nih.gov/pubmed/28754150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13104-017-2687-5 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|